Detail

Gadofosveset trisodium

Description

Name: Gadofosveset trisodium
Type: small molecule
Groups: approved
Indication: Gadofosveset trisodium is indicated for use as a contrast agent in magnetic resonance angiography (MRA) to evaluate aortoiliac occlusive disease (AIOD) in adults with known or suspected peripheral vascular disease.
Accession Number: DB06705 ( DB06705)
Description: Gadofosveset trisodium is an intravenous contrast agent used with magnetic resonance angiography(MRA), which is a non-invasive way of imaging blood vessels. The agent allows for the vascular system to be imaged more clearly by the MRA. In this way, gadofosveset trisodium is used to help diagnose certain disorders of the heart and blood vessels.
Structure:
Prescription Products:
NameDosageStrengthRouteMarketing StartMarketing EndCountry
Ablavarsolution244 mgintravenous12-10-2010Canada
Ablavarinjection, solution244 mg/mLintravenous12-12-2008US
Vasovistsolution244 mgintravenous20-08-200706-08-2009Canada

Generic Prescription Products: Not Available
Over the Counter Products: Not Available
International Brands
  • No Brands

Brand Names
  • No Brands

Brand Mixtures
Brand NameIngredients
AblavarGadofosveset trisodium
AblavarGadofosveset trisodium
VasovistGadofosveset trisodium

Categories
  • Contrast Media
  • Diagnostic Agents

Pharmacology

Indication: Gadofosveset trisodium is indicated for use as a contrast agent in magnetic resonance angiography (MRA) to evaluate aortoiliac occlusive disease (AIOD) in adults with known or suspected peripheral vascular disease.
Pharmacodynamics: Not Available
Mechanism of action: Gadofosveset binds reversibly to endogenous serum albumin resulting in longer vascular residence time than non-protein binding contrast agents. The binding to serum albumin also increases the magnetic resonance relaxivity of gadofosveset and decreases the relaxation time (Tl) of water protons resulting in an increase in signal intensity (brightness) of blood.
Absorption: Not Available
Volume of distribution:
    48 ± 16 mL/kg

Protein binding: 80-90%
Metabolism: Not Available
Route of elimination: Gadofosveset is eliminated primarily in the urine with approximately 83.5% of an injected dose excreted in the urine over 14 days. Ninety-four percent (94%) of urinary excretion occurs in the first 72 hours. A small portion of gadofosveset dose is recovered in feces (approximately 4.7%).
Half life: 18.5 hours
Clearance: Not Available
Toxicity: Gadolinium-based contrast agents increase the risk for nephrogenic systemic fibrosis (NSF) in patients with acute or chronic severe renal insufficiency (glomerular filtration rate < 30 mL/min/1.73m²).
Affected organisms
  • Not Available

SNP Mediated Adverse Drug Reactions
  • Not Available

Pharmacoeconomics

Manufacturers:
  • Not Available

Packagers:
  • Not Available

Dosage forms
FormRouteStrength
Injection, solutionintravenous244 mg/mL
Solutionintravenous244 mg

Prices
Unit descriptionCostUnit

Patents
CountryPatent NumberApprovedExpires (estimated)
2211100Canada2007-03-202016-01-16
2304461Canada2008-10-142018-08-17

Interactions

Drug Interactions
DrugInteraction

Food Interactions:
  • Not Available

Taxonomy

Kingdom: Organic compounds
Super Class: Not Available
Class: Not Available
Sub Class: Not Available
Direct Parent: Not Available
Alternative Parents:
  • Alpha amino acids
  • Carbonyl compounds
  • Carboxylic acid salts
  • Carboxylic acids
  • Dialkyl phosphates
  • Diphenylmethanes
  • Hydrocarbon derivatives
  • Organic phosphoric acids
  • Organic sodium salts
  • Organic zwitterions
  • Phosphoethanolamines
  • Trialkylamines

substituent:
  • Alkyl phosphate
  • Alpha-amino acid
  • Alpha-amino acid or derivatives
  • Amine
  • Aromatic homomonocyclic compound
  • Benzenoid
  • Carbonyl group
  • Carboxylic acid
  • Carboxylic acid salt
  • Dialkyl phosphate
  • Diphenylmethane
  • Hydrocarbon derivative
  • Monocyclic benzene moiety
  • Organic alkali metal salt
  • Organic phosphate
  • Organic phosphoric acid derivative
  • Organic salt
  • Organic sodium salt
  • Organic zwitterion
  • Organonitrogen compound
  • Organooxygen compound
  • Pentacarboxylic acid or derivatives
  • Phosphoethanolamine
  • Phosphoric acid ester
  • Tertiary aliphatic amine
  • Tertiary amine

References

Synthesis Reference: Not Available
General Reference: # Raman FS, Nacif MS, Cater G, Gai N, Jones J, Li D, Sibley CT, Liu S, Bluemke DA: 3.0-T whole-heart coronary magnetic resonance angiography: comparison of gadobenate dimeglumine and gadofosveset trisodium. Int J Cardiovasc Imaging. 2013 Mar 21. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/23515949 # Hrdina L, Kocher M, Herman M, Cerna M, Kozak J, Tudos Z, Mahathmakanthi S, Langova K: Comparison of the quality of lower limb magnetic resonance angiographies performed with different paramagnetic contrast agents in relation to body mass index and ejection fraction. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2012 Jun;156(2):164-70. doi: 10.5507/bp.2011.058. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/22660207 # Thouet T, Schnackenburg B, Kokocinski T, Fleck E, Nagel E, Kelle S: Visualization of chronic myocardial infarction using the intravascular contrast agent MS-325 (gadofosveset) in patients. ScientificWorldJournal. 2012;2012:236401. doi: 10.1100/2012/236401. Epub 2012 Mar 12. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/22536125 # Milot L, Haider M, Foster L, McGregor C, Law C: Gadofosveset trisodium in the investigation of focal liver lesions in noncirrhotic liver: Early experience. J Magn Reson Imaging. 2012 Sep;36(3):738-42. doi: 10.1002/jmri.23650. Epub 2012 Apr 5. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/22488745 # Caravan P: Protein-targeted gadolinium-based magnetic resonance imaging (MRI) contrast agents: design and mechanism of action. Acc Chem Res. 2009 Jul 21;42(7):851-62. doi: 10.1021/ar800220p. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/19222207
External Links:
ResourceLink
Drugs.comhttp://www.drugs.com/mtm/gadofosveset-trisodium.html

ATC Codes:
  • Array

AHFS Codes:
  • Not Available

MSDS: Download
SiteLock

© Copyright 2022 The Purple Society, Purple Gladiator, Trialsmap, The Purple Drug Guide, and One Person CAN Make A Difference! are all registered trademarks of The Purple Society. The Purple Society, a not-for-profit, section 501(c)(3) #273785281.

The Purple Society website is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through this site should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, you should consult your health care provider.

CONTACT US

The Purple Society team is here for you 24 hours a day, 7 days a week. Send us an email and we'll get right back to you.

Sending
or

Log in with your credentials

Forgot your details?